Overview Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer Status: Recruiting Trial end date: 2025-11-01 Target enrollment: Participant gender: Summary Disease recurrence and progression is a major issue in high risk non-muscle-invasive bladder cancer (NMIBC). The current study compares two adjuvant instillation therapies in the treatment of high risk NMIBC. After resection of the tumour(s), patients will receive either traditional regimen of Bacillus Calmette-Guérin (BCG) instillations or combination treatment consisting of sequential BCG-instillations and mitomycin C instillations administered with electromotive drug administration (EMDA) device. Phase: Phase 3 Details Lead Sponsor: Turku University HospitalCollaborator: FinnbladderTreatments: BCG VaccineMitomycinMitomycins